Vés al contingut

A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

  • Codi protocol: VX18-445-110
  • Codi EudraCT: 2019-000833-37
  • Grup de recerca: Pneumologia
  • Servei: Pneumologia
  • Investigador/a principal:  Álvarez Fernandez, Antonio
  • Fase: Fase III
  • Estat: Reclutant voluntaris